Coalition for Epidemic Preparedness Innovations

Coalition for Epidemic Preparedness Innovations
Name	Coalition for Epidemic Preparedness Innovations
Formation	2017
Type	Non-profit foundation
Headquarters	Oslo, Norway
Region served	Global
Leader title	CEO
Leader name	Johns Hopkins Bloomberg School of Public Health

Coalition for Epidemic Preparedness Innovations is an international non-profit foundation formed in 2017 to finance and coordinate vaccine development for emerging infectious diseases. It operates at the nexus of Bill & Melinda Gates Foundation, Wellcome Trust, Norwegian Ministry of Health and Care Services donors, and global public health institutions to shorten vaccine development timelines for outbreaks such as Ebola virus epidemic in West Africa, Zika virus epidemic, and the COVID-19 pandemic. The organization convenes researchers, biotechnology firms, pharmaceutical companies, and multilateral agencies to support vaccine platforms, clinical trials, and global distribution mechanisms.

History

Established in response to lessons from the 2014 Ebola outbreak in West Africa and the rise of novel threats like MERS coronavirus and Zika virus, the foundation was announced with support from national actors including Norway and philanthropic organizations such as Wellcome Trust and Bill & Melinda Gates Foundation. Early efforts emphasized preparedness for priority pathogens identified by World Health Organization research agendas and aligned with the Global Health Security Agenda. During the 2018 Ebola virus epidemic in Équateur province, the organization accelerated candidate vaccines initially developed by teams at National Institutes of Health, Institut Pasteur, and University of Oxford partners. The rapid mobilization during the COVID-19 pandemic highlighted prior investments in platform technologies pioneered by entities such as Moderna, AstraZeneca, and BioNTech. The group's timeline intersects with major outbreak responses, including the 2016 Zika virus epidemic and subsequent vaccine and diagnostics consortia.

Governance and Funding

The foundation is governed by a board comprising representatives from public and private sectors, including figures drawn from institutions like Gavi, the Vaccine Alliance, World Health Organization, Coalition for Epidemic Preparedness Innovations donors (not linked), and national research agencies such as United Kingdom Research and Innovation and US National Institutes of Health. Funding streams combine commitments from sovereign donors—examples include Norway, Japan, Germany—and philanthropic partners like Wellcome Trust and Bill & Melinda Gates Foundation. The governance model balances contributions from multilateral institutions such as World Bank and private industry partners like GlaxoSmithKline and Sanofi through advisory committees and scientific advisory boards featuring experts from Harvard University, Imperial College London, and Johns Hopkins University. Financial oversight aligns with international aid modalities employed by agencies including United Nations Development Programme and European Commission funding mechanisms.

Mission and Programs

The stated mission focuses on accelerating vaccine development for emerging pathogens identified by the World Health Organization R&D Blueprint and ensuring equitable access through global delivery networks like Gavi, the Vaccine Alliance. Programs include investment in platform technologies developed by companies such as Moderna, Pfizer, and CureVac, support for clinical trial networks coordinated with London School of Hygiene & Tropical Medicine and LSHTM collaborators, and advanced purchase commitments to incentivize manufacturing scale-up by firms including AstraZeneca and Johnson & Johnson. The foundation’s portfolio spans preclinical research partnerships with academic centers such as Massachusetts Institute of Technology and capacity-building initiatives in low- and middle-income countries coordinated with African Union health agencies and Médecins Sans Frontières logistical expertise.

Research and Development Initiatives

R&D investments prioritize rapid-response platform technologies—mRNA, viral vectors, protein subunits—mirroring innovations by companies like BioNTech, Moderna, and Novavax. The organization has funded clinical development pathways for candidates addressing pathogens on the WHO priority pathogens list, supporting trials in collaboration with institutions such as University of Oxford, Institut Pasteur, and Seattle Children’s Research Institute. Initiatives include funding vaccine antigen design leveraging structural biology advances from laboratories at Scripps Research, longitudinal immunology studies with researchers at Fred Hutchinson Cancer Research Center, and manufacturing scale projects with contract manufacturers including Emergent BioSolutions. The entity also invests in regulatory science dialogues involving agencies such as European Medicines Agency and US Food and Drug Administration to expedite emergency use authorizations during outbreaks.

Partnerships and Collaborations

Strategic collaborations link the foundation with multilateral organizations like World Health Organization, Gavi, the Vaccine Alliance, and UNICEF to coordinate procurement and distribution during health emergencies. Academic partnerships include University of Oxford, Harvard T.H. Chan School of Public Health, and Imperial College London for trial design and epidemiological modeling, while industry alliances span AstraZeneca, Moderna, Pfizer, and Novavax for manufacturing and platform access. The foundation engages with regional bodies such as the African Centres for Disease Control and Prevention and national public health institutes including US Centers for Disease Control and Prevention and Public Health England for surveillance and site readiness. Collaborations with philanthropic organizations—Wellcome Trust, Gates Foundation—and financial institutions like World Bank enable pooled financing instruments and advance market commitments.

Impact and Criticism

Impact includes accelerated development of multiple vaccine candidates, notably contributions to rapid COVID-19 vaccine timelines through support for platforms used by Moderna and AstraZeneca, facilitation of clinical trials in outbreak settings, and investments in manufacturing capacity across regions in partnership with Gavi, the Vaccine Alliance and UNICEF. Critics point to challenges in equitable access debates involving high-income country allocations, contractual transparency concerns raised by Médecins Sans Frontières, and governance questions about industry influence highlighted in analyses involving Transparency International and academic critiques from researchers at London School of Economics. Evaluations by policy institutes such as Chatham House and RAND Corporation recommend strengthening mechanisms for technology transfer to institutions in Africa and Southeast Asia and increasing public reporting on procurement agreements to address equity and accountability gaps.

Category:Public health organizations